20-minute watch
| Talk 1
of 4
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda
Institut Català d’Oncologia, Barcelona, Spain
Dr Anna Sureda of the Institut Català d’Oncologia, Barcelona,
Spain reviews clinical trial data and real-world evidence that pave the way to CAR T as SoC in 2L LBCL
